Allevi and Lonza, a major Swiss CDMO, have formed a collaboration to bring the elements needed for 3D bioprinting together. Combining Lonza’s primary cells and media with Allevi’s 3D bioprinters and bioink production capabilities will empower researchers with the tools needed for plug-and-play bioprinting.
One of the biggest setbacks on bioprinting advancements is the availability of viable and functional cellular materials. Much like in AM, the technologies may be slow but they are there and ready for creating commercial applications, they are just not been exploited to the fullest.
Allevi is one of the companies developing affordable bioprinting hardware and is dedicated to providing high-quality materials for every step of the 3D bioprinting workflow, making it easy to design, engineer, and manufacture 3D tissues. Their 3D bioprinters and bioinks are used by leading researchers globally in research drug discovery and tissue engineering.
Lonza Biosciences is a global leader in cell biology solutions, offering a broad range of high-quality human-derived primary cells, stem cells and supporting culture media that are ideally suited for 3D cell culture and 3D bioprinting.
3D bioprinting has been gathering a lot of media attention recently, as new potential applications seem closer to exploring commercial viability. Several scientists now agree that bioprinting is a promising technology for engineering of complex 3D tissues needed in many areas of in vitro drug discovery research. High-quality cells are the essential building block for creating 3D bioprinting constructs and can be printed in physiological relevant patterns using this technology.
Lonza collaborates with selected providers of 3D printing technology to bring the best cell and media tools to 3D bioprinting applications. Allevi customers will now have access to Lonza primary cells and media for use in Allevi’s protocols for 3D bioprinting.
